Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer (Q33214444)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

title

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

main subject

etoposide

1 reference

based on heuristic

inferred from title

cisplatin

1 reference

based on heuristic

inferred from title

author

David Cunningham

series ordinal

2

object named as

Cunningham D

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

author name string

Rao S

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Hawkins RE

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Hill ME

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Smith D

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Daniel F

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Ross PJ

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Oates J

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Norman AR

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

published in

British Journal of Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

volume

92

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

issue

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

page(s)

1650-1654

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

cites work

Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2362051

retrieved

21 June 2018

Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602576

retrieved

21 January 2018

Cholangiocarcinoma: the "other" liver cancer on the rise

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15856037

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15856037

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/15856037

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/SJ.BJC.6602576

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

Dimensions Publication ID

1052616134

0 references

PMC publication ID

2362051

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

PubMed publication ID

15856037

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15856037

retrieved

24 July 2017

ResearchGate publication ID

7882086

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33214444&oldid=2195145912"